These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 31599845)
21. Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder. Carter JA; Dammerman R; Frost M J Med Econ; 2017 Aug; 20(8):893-901. PubMed ID: 28604141 [TBL] [Abstract][Full Text] [Related]
22. Estimated effectiveness and cost-effectiveness of opioid use disorder treatment under proposed U.S. regulatory relaxations: A model-based analysis. Qian G; Humphreys K; Goldhaber-Fiebert JD; Brandeau ML Drug Alcohol Depend; 2024 Mar; 256():111112. PubMed ID: 38335797 [TBL] [Abstract][Full Text] [Related]
23. Medications for management of opioid use disorder. Koehl JL; Zimmerman DE; Bridgeman PJ Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869 [TBL] [Abstract][Full Text] [Related]
24. Healthcare utilization and costs associated with treatment for opioid dependence. Shah A; Duncan M; Atreja N; Tai KS; Gore M J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915 [TBL] [Abstract][Full Text] [Related]
25. Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance. Klaman SL; Isaacs K; Leopold A; Perpich J; Hayashi S; Vender J; Campopiano M; Jones HE J Addict Med; 2017; 11(3):178-190. PubMed ID: 28406856 [TBL] [Abstract][Full Text] [Related]
26. Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study. Larochelle MR; Wakeman SE; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM Med Care; 2020 Oct; 58(10):919-926. PubMed ID: 32842044 [TBL] [Abstract][Full Text] [Related]
27. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. Gisev N; Shanahan M; Weatherburn DJ; Mattick RP; Larney S; Burns L; Degenhardt L Addiction; 2015 Dec; 110(12):1975-84. PubMed ID: 26212260 [TBL] [Abstract][Full Text] [Related]
28. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History. Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674 [TBL] [Abstract][Full Text] [Related]
29. Use of naltrexone in treating opioid use disorder in pregnancy. Towers CV; Katz E; Weitz B; Visconti K Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396 [TBL] [Abstract][Full Text] [Related]
30. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women. Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191 [TBL] [Abstract][Full Text] [Related]
31. Update on pharmacotherapy for treatment of opioid use disorder. Ayanga D; Shorter D; Kosten TR Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745 [TBL] [Abstract][Full Text] [Related]
32. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16. Yang JC; Roman-Urrestarazu A; Brayne C PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120 [TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Bansback N; Guh D; Oviedo-Joekes E; Brissette S; Harrison S; Janmohamed A; Krausz M; MacDonald S; Marsh DC; Schechter MT; Anis AH Addiction; 2018 Jul; 113(7):1264-1273. PubMed ID: 29589873 [TBL] [Abstract][Full Text] [Related]
34. Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis. Calcaterra SL; Klie KA Obstet Gynecol; 2020 Apr; 135(4):975. PubMed ID: 32217961 [No Abstract] [Full Text] [Related]
36. Comparison of costs and utilization among buprenorphine and methadone patients. Barnett PG Addiction; 2009 Jun; 104(6):982-92. PubMed ID: 19466922 [TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids. Claypool AL; DiGennaro C; Russell WA; Yildirim MF; Zhang AF; Reid Z; Stringfellow EJ; Bearnot B; Schackman BR; Humphreys K; Jalali MS JAMA Health Forum; 2023 May; 4(5):e231080. PubMed ID: 37204803 [TBL] [Abstract][Full Text] [Related]
38. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. Meader N Drug Alcohol Depend; 2010 Apr; 108(1-2):110-4. PubMed ID: 20074867 [TBL] [Abstract][Full Text] [Related]
39. Services for perinatal patients with opioid use disorder: a comprehensive Baltimore City-wide 2023 assessment. Ratner JA; Kirschner JH; Spencer B; Terplan M Addict Sci Clin Pract; 2024 Oct; 19(1):73. PubMed ID: 39407344 [TBL] [Abstract][Full Text] [Related]
40. Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting. De Aquino JP; Fairgrieve C; Klaire S; Garcia-Vassallo G J Addict Med; 2020; 14(5):e271-e273. PubMed ID: 32011408 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]